


Hungary

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Per capital	Change since previous survey: ▲ Improvement ▼ Decline		2009	9 2012 2015				2018	
Organisation Comprehensive Care Centres (CCCs)	International units	Factor VIII	6.39	A	8.32	A	9.33	A	12.63
Mamophilla Treatment Centres Yes	per capita	Factor IX	0.52	A	0.65	•	0.60	•	0.00
National Haemophilla Council or Co-ordinating Group Number of groups in decision-making on haemophilla care Number of groups in decision-making on haemophilla care Number of groups choosing haemophilia treatment products National Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Home Treatment Rob people with haemophilia using home treatment Treatment delivered to the patient's home Prophylaxis treatment availability Prophylaxis t	Organisation	Comprehensive Care Centres (CCC's)	No		No	A	Yes		Yes
Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products	of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
Number of groups choosing haemophilia treatment products Alfational Tender for procurement of factor concentrates Treatment Home Treatment Home Treatment Home Treatment Home Treatment Regimens % of people with haemophilia using home treatment Treatment delivered to the patient's home Prophylaxis treatment availability Res Children currently on prophy (%) Adults currently on prophy (%) Access to IT (% of people with inhibitors) Emergency medicine and acute surgery Peacitartics Infectious disease specialists (especially HIV) Res Infectious disease specialists (especially HIV) Res Infectious disease specialists (especially HIV) Res Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management Ceneral surgery Urology Share of Expected Haemophilia A Haemophilia B Resombinant factor concentrate Never		National Haemophilia Council or Co-ordinating Group	Yes	•	No		No		No
Treatment Home Treatment of factor concentrates Yes Yes Yes Yes Yes regimens % of people with haemophilia using home treatment % No		Number of groups in decision-making on haemophilia care	3	•	1	A	2		2
Treatment Home Treatment regimens % of people with haemophilia using home treatment 76-100% 751-75% 76-100% No		Number of groups choosing haemophilia treatment products	2	A	3	▼	2		2
Regimens		National Tender for procurement of factor concentrates	Yes		Yes		Yes		Yes
Treatment delivered to the patient's home Prophylaxis freatment availability Yes Yes Some Prophylaxis freatment availability 76-100% 76-100% 76-100% 76-100% 76-100% Adults currently on prophy (%) 76-100% 76-100% 26-50%	Treatment	Home Treatment	Yes		Yes		Yes		Yes
Prophylaxis treatment availability Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to If (% of people with inhibitors) Access to Emergency medicine and acute surgery Access to Mexer Never N	regimens	% of people with haemophilia using home treatment	76-100%	•	51-75%	A	76-100%		76-100%
Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to ITI (% of people with inhibitors) Access to Emergency medicine and acute surgery Specialist services Paediatrics Pa		Treatment delivered to the patient's home	No		No		No		No
Adults currently on prophy (%)		Prophylaxis treatment availability	Yes		Yes	▼	Some	A	Yes
Access to ITI (% of people with inhibitors) Access to Emergency medicine and acute surgery Specialist services Paediatrics Infectious disease specialists (especially HIV) Pes Yes Yes Yes Yes Yes Yes Yes Yes Yes Y		Children currently on prophy (%)	76-100%		76-100%		76-100%		76-100%
Access to Emergency medicine and acute surgery Pacidiartics Pacidiartics Pacidiartics Pacidiartics Pacidiartics Pacidiartics Pacidiartics Pacidiartics Pacidiartics Phesionary Pasma-derived factor concentrate therapy Plasma Pasma-derived factor concentrate Always Always Plasma Pasma-derived factor concentrate Always Always Always Pasma-derived factor concentrate Always Always Plasma Pasma-derived factor concentrate Plasma-derived factor concentrate Plasma Plasma Plasma Plasma-derived factor concentrate Plasma Plasma Plasma Plasma-derived factor concentrate Plasma Plasma Plasma-derived factor concentrate Plasma Plasma Plasma-derived factor concentrate Plasma Plasma Plasma Plasma-derived factor concentrate Plasma Plasm		Adults currently on prophy (%)	76-100%	•	26-50%		26-50%	A	51-75%
Specialist services Paediatrics Paediatr		Access to ITI (% of people with inhibitors)	100%	•	76-99%		76-99%		76-99%
Infectious disease specialists (especially HIV) Hepatology Rheumatology Rometimes Rometimes Sometimes Rhever Rhever Rhever Rhever Rhever Rhever Rheumatology Rarely Rhever Rheumatology Rarely Rare	Access to	Emergency medicine and acute surgery	Yes		Yes		Yes		Yes
Hepatology Rheumatology Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Rheumatology Rheumatology Yes Yes Y Sometimes Y Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes Sometimes Never Nev	specialist services	Paediatrics	Yes		Yes		Yes		Yes
Rheumatology Orthopaedics Physiotherapy Oesterrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Rheumatology Orthopaedics Yes Yes Yosometimes Yometimes Sometimes Sometimes Sometimes Sometimes Sometimes Never		Infectious disease specialists (especially HIV)	Yes		Yes		Yes	•	Sometimes
Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate Ves V Sometimes V Never Sometimes V Never		Hepatology	Yes		Yes	•	Sometimes		Sometimes
Physiotherapy Dentistry Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate Ves Vometimes Ves Never		Rheumatology	Yes	▼	Sometimes		Sometimes	•	Never
Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia A Haemophilia B Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Cryoprecipitate Ves Vacer Never		Orthopaedics	Yes		Yes	▼	Sometimes		Sometimes
Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Cryop recipitate Wever Always Alway		Physiotherapy	Yes	•	Sometimes		Sometimes		Sometimes
Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Therapy Plasma Plasma Plasma Plasma-derived factor concentrate Cryoprecipitate Wever Never		Dentistry	Yes	▼	Sometimes	▼	Never		Never
Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia A Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate Where Never		Obstetrics and Gynaecology					Sometimes	•	Never
Pain management General surgery Urology Share of Expected Bleeding Disorder Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryoprecipitate VWD replacement VWD replacement VWD replacement Very Sometimes Sometimes Sometimes Sometimes Sometimes Never		Genetics			Sometimes		Sometimes	•	Never
General surgery Urology Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Haemophilia Recombinant factor concentrate Plasma Plasma Plasma-derived factor concentrate Always Never		Social and psychological support			Never		Never		Never
Urology Sometimes ▼ Never Share of Expected Haemophilia A 83% ▼ 80% △ 86% △ 92% Bleeding Disorder Haemophilia B 65% △ 69% △ 74% △ 77% Prevalence von Willebrand Disease 14% ▼ 13% △ 14% △ 15% Haemophilia Pasma-derived factor concentrate Always Always Always Always Always Always Rarely Rarely Rarely Rarely Never Never Never Never Never Never Rarely Rare		Pain management			Never		Never		Never
Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease 14% 13% 14% 15% Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Always Always Plasma Never		General surgery			Yes	▼	Sometimes		Sometimes
Bleeding Disorder Haemophilia B Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Plasma Plasma Plasma-derived factor concentrate Plasma-derived factor concentrate Plasma-derived factor concentrate Plasma-derived factor concentrate Never N		Urology			Sometimes		Sometimes	•	Never
Prevalence von Willebrand Disease 14% ▼ 13% ▲ 14% ▲ 15% Haemophilia Pasma-derived factor concentrate Always Always Always Always Always Always Rarely Rarely Rarely Rarely Never Rarely Rarel	Share of Expected	Haemophilia A	83%	_	80%	A	86%	A	92%
Haemophilia Pasma-derived factor concentrate Always Always Always Plasma Recombinant factor concentrate Always Always Plasma Recombinant factor concentrate Always Always Plasma Rarely Rarely Rarely Plasma Never Neve	Bleeding Disorder	Haemophilia B	65%	A	69%	A	74%	A	77%
replacement Recombinant factor concentrate Always Always V Rarely therapy Plasma Never	Prevalence		14%	▼	13%	A	14%	A	15%
therapy Plasma Never Ne	Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
Cryoprecipitate Never Never Never Never VWD replacement Plasma-derived factor concentrate Always Always ▼ Rarely Rarely therapy DDAVP Rarely Rarely Rarely Plasma Never Never	replacement	Recombinant factor concentrate	Always		Always	•	Rarely		Rarely
VWD replacement Plasma-derived factor concentrate Always Always Rarely therapy DDAVP Rarely Rarely Plasma Never Never	therapy	Plasma	Never		Never		Never		Never
therapy DDAVP Rarely Plasma Rarely Never Never Rarely Rarely		Cryoprecipitate	Never		Never		Never		Never
Plasma Never Never	VWD replacement	Plasma-derived factor concentrate	Always		Always	•	Rarely		Rarely
	therapy	DDAVP	Rarely				Rarely		Rarely
Cryoprecipitate Never Never		Plasma	Never		Never				
		Cryoprecipitate	Never		Never				